Fennec Pharmaceuticals Inc.

United States of America

Back to Profile

1-24 of 24 for Fennec Pharmaceuticals Inc. Sort by
Query
Aggregations
IP Type
        Patent 16
        Trademark 8
Jurisdiction
        United States 17
        Europe 4
        World 3
Date
New (last 4 weeks) 1
2025 November (MTD) 1
2025 (YTD) 1
2024 6
2023 5
See more
IPC Class
A61K 33/04 - Sulfur, selenium or telluriumCompounds thereof 15
A61K 33/243 - PlatinumCompounds thereof 13
A61K 47/02 - Inorganic compounds 13
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids 13
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids 13
See more
NICE Class
05 - Pharmaceutical, veterinary and sanitary products 6
35 - Advertising and business services 2
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services 2
Status
Pending 6
Registered / In Force 18

1.

ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF

      
Application Number 19275772
Status Pending
Filing Date 2025-07-21
First Publication Date 2025-11-13
Owner Fennec Pharmaceuticals, Inc. (USA)
Inventor Smith, Alexander

Abstract

Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.

IPC Classes  ?

  • A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/08 - Solutions
  • A61K 33/04 - Sulfur, selenium or telluriumCompounds thereof
  • A61K 33/243 - PlatinumCompounds thereof
  • A61K 47/02 - Inorganic compounds
  • A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids

2.

Anhydrous Sodium Thiosulfate and Formulations Thereof

      
Application Number 18503027
Status Pending
Filing Date 2023-11-06
First Publication Date 2024-10-24
Owner Fennec Pharmaceuticals Inc. (USA)
Inventor
  • Lovelace, Thomas Claiborne
  • Moore, Iii, Joseph Alexander
  • Lee, Christopher Mckinnon
  • Kirschner, Daniel Logan

Abstract

Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.

IPC Classes  ?

  • A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/08 - Solutions
  • A61K 33/04 - Sulfur, selenium or telluriumCompounds thereof
  • A61K 33/243 - PlatinumCompounds thereof
  • A61K 47/02 - Inorganic compounds
  • A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids

3.

Miscellaneous Design

      
Application Number 019076046
Status Registered
Filing Date 2024-09-06
Registration Date 2025-01-09
Owner Fennec Pharmaceuticals, Inc. (USA)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations, namely, sodium thiosulfate used for the prevention of ototoxicity from cisplatin in paediatric patients.

4.

Miscellaneous Design

      
Serial Number 98729787
Status Pending
Filing Date 2024-09-03
Owner Fennec Pharmaceuticals, Inc. ()
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations, namely, sodium thiosulfate used for the prevention of ototoxicity from cisplatin in pediatric patients

5.

Therapeutic uses for sodium thiosulfate formulations

      
Application Number 18606860
Grant Number 12311026
Status In Force
Filing Date 2024-03-15
First Publication Date 2024-07-04
Grant Date 2025-05-27
Owner Fennec Pharmaceuticals, Inc. (USA)
Inventor
  • Smith, Alexander
  • Raykov, Rostislav Christov

Abstract

Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.

IPC Classes  ?

  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/08 - Solutions
  • A61K 33/04 - Sulfur, selenium or telluriumCompounds thereof
  • A61K 33/243 - PlatinumCompounds thereof
  • A61K 47/02 - Inorganic compounds
  • A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
  • A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

6.

Anhydrous Sodium Thiosulfate and Formulations Thereof

      
Application Number 18503035
Status Pending
Filing Date 2023-11-06
First Publication Date 2024-05-23
Owner Fennec Pharmaceuticals Inc. (USA)
Inventor
  • Lovelace, Thomas Claiborne
  • Moore, Iii, Joseph Alexander
  • Lee, Christopher Mckinnon
  • Kirschner, Daniel Logan

Abstract

Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.

IPC Classes  ?

  • A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/08 - Solutions
  • A61K 33/04 - Sulfur, selenium or telluriumCompounds thereof
  • A61K 33/243 - PlatinumCompounds thereof
  • A61K 47/02 - Inorganic compounds
  • A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids

7.

ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF

      
Application Number 18375162
Status Pending
Filing Date 2023-09-29
First Publication Date 2024-02-08
Owner Fennec Pharmaceuticals Inc (USA)
Inventor
  • Lovelace, Thomas Claiborne
  • Moore, Iii, Joseph Alexander
  • Lee, Christopher Mckinnon
  • Kirschner, Daniel Logan

Abstract

Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.

IPC Classes  ?

  • A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
  • A61K 33/243 - PlatinumCompounds thereof
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/08 - Solutions
  • A61K 33/04 - Sulfur, selenium or telluriumCompounds thereof
  • A61K 47/02 - Inorganic compounds
  • A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids

8.

ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF

      
Application Number 18111849
Status Pending
Filing Date 2023-02-20
First Publication Date 2023-06-29
Owner
  • ADS PHARMA CONSULTING, LLC (USA)
  • FENNEC PHARMACEUTICALS, INC. (USA)
Inventor
  • Lovelace, Thomas Claiborne
  • Moore, Iii, Joseph Alexander
  • Lee, Christopher Mckinnon
  • Kirschner, Daniel Logan

Abstract

Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.

IPC Classes  ?

  • A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/08 - Solutions
  • A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
  • A61K 33/243 - PlatinumCompounds thereof
  • A61K 47/02 - Inorganic compounds
  • A61K 33/04 - Sulfur, selenium or telluriumCompounds thereof

9.

Therapeutic uses for sodium thiosulfate formulations

      
Application Number 17992715
Grant Number 11964018
Status In Force
Filing Date 2022-11-22
First Publication Date 2023-05-25
Grant Date 2024-04-23
Owner Fennec Pharmaceuticals Inc. (USA)
Inventor Smith, Alexander

Abstract

Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.

IPC Classes  ?

  • A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/08 - Solutions
  • A61K 33/04 - Sulfur, selenium or telluriumCompounds thereof
  • A61K 33/243 - PlatinumCompounds thereof
  • A61K 47/02 - Inorganic compounds
  • A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids

10.

PEDMARQSI

      
Application Number 018858616
Status Registered
Filing Date 2023-04-05
Registration Date 2023-08-26
Owner Fennec Pharmaceuticals, Inc. (USA)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations, namely, sodium thiosulfate used for the prevention of ototoxicity from cisplatin in paediatric patients.

11.

Therapeutic uses for sodium thiosulfate formulations

      
Application Number 17992703
Grant Number 11998604
Status In Force
Filing Date 2022-11-22
First Publication Date 2023-03-30
Grant Date 2024-06-04
Owner Fennec Pharmaceuticals Inc. (USA)
Inventor Smith, Alexander

Abstract

Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.

IPC Classes  ?

  • A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/08 - Solutions
  • A61K 33/04 - Sulfur, selenium or telluriumCompounds thereof
  • A61K 33/243 - PlatinumCompounds thereof
  • A61K 47/02 - Inorganic compounds
  • A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids

12.

Therapeutic uses for sodium thiosulfate and formulations

      
Application Number 17992707
Grant Number 11992530
Status In Force
Filing Date 2022-11-22
First Publication Date 2023-03-30
Grant Date 2024-05-28
Owner Fennec Pharn ceuticals Inc. (USA)
Inventor Smith, Alexander

Abstract

Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.

IPC Classes  ?

  • A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/08 - Solutions
  • A61K 33/04 - Sulfur, selenium or telluriumCompounds thereof
  • A61K 33/243 - PlatinumCompounds thereof
  • A61K 47/02 - Inorganic compounds
  • A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids

13.

FENNEC HEARS HEARING EDUCATION, ACCESS & REIMBURSEMENT SUPPORT

      
Application Number 018813212
Status Registered
Filing Date 2022-12-21
Registration Date 2023-06-03
Owner Fennec Pharmaceuticals, Inc. (a Delaware Corporation) (USA)
NICE Classes  ?
  • 35 - Advertising and business services
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Patient administration services, namely, enrolling patients in the patient assistance programs of others to assist them in saving money on their prescription medications; Administration of patient pharmaceutical reimbursement programs; administering a patient support and assistance program for obtaining reimbursement for prescription medicines. Providing medical information about the treatment and prevention of ototoxicity from cisplatin in pediatric patients.

14.

Anhydrous sodium thiosulfate and formulations thereof

      
Application Number 17871825
Grant Number 11617793
Status In Force
Filing Date 2022-07-22
First Publication Date 2022-12-01
Grant Date 2023-04-04
Owner
  • ADS PHARMA CONSULTING, LLC (USA)
  • FENNEC PHARMACEUTICALS, INC. (USA)
Inventor
  • Lovelace, Thomas Claiborne
  • Moore, Iii, Joseph Alexander
  • Lee, Christopher Mckinnon
  • Kirschner, Daniel Logan

Abstract

Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.

IPC Classes  ?

  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/08 - Solutions
  • A61K 33/04 - Sulfur, selenium or telluriumCompounds thereof
  • A61K 33/243 - PlatinumCompounds thereof
  • A61K 47/02 - Inorganic compounds
  • A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
  • A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

15.

Anhydrous sodium thiosulfate and formulations thereof

      
Application Number 17849477
Grant Number 11510984
Status In Force
Filing Date 2022-06-24
First Publication Date 2022-10-13
Grant Date 2022-11-29
Owner
  • ADS PHARMA CONSULTING, LLC (USA)
  • FENNEC PHARMACEUTICALS, INC. (USA)
Inventor
  • Lovelace, Thomas Claiborne
  • Moore, Iii, Joseph Alexander
  • Lee, Christopher Mckinnon
  • Kirschner, Daniel Logan

Abstract

Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.

IPC Classes  ?

  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/08 - Solutions
  • A61K 33/04 - Sulfur, selenium or telluriumCompounds thereof
  • A61K 33/243 - PlatinumCompounds thereof
  • A61K 47/02 - Inorganic compounds
  • A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
  • A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

16.

FENNEC HEARS HEARING EDUCATION, ACCESS & REIMBURSEMENT SUPPORT

      
Serial Number 97467771
Status Registered
Filing Date 2022-06-21
Registration Date 2024-01-23
Owner Fennec Pharmaceuticals, Inc. ()
NICE Classes  ?
  • 35 - Advertising and business services
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Patient advocacy services, namely, promoting public awareness of pharmaceutical discount opportunities for underserved and needy communities by means of public advocacy and business administration of the patient assistance programs of others by enrolling patients in the assistance programs to assist them in saving money on their prescription medications; business administration of patient pharmaceutical reimbursement programs; business administration of a patient support and assistance program for obtaining reimbursement for prescription medicines Providing medical information and educational information in the field of medicine about the treatment and prevention of ototoxicity from cisplatin in pediatric patients

17.

Anhydrous sodium thiosulfate and formulations thereof

      
Application Number 17005997
Grant Number 11291728
Status In Force
Filing Date 2020-08-28
First Publication Date 2021-01-21
Grant Date 2022-04-05
Owner
  • ADS PHARMA CONSULTING, LLC (USA)
  • FENNEC PHARMACEUTICALS, INC. (USA)
Inventor
  • Lovelace, Thomas Claiborne
  • Moore, Iii, Joseph Alexander
  • Lee, Christopher Mckinnon
  • Kirschner, Daniel Logan

Abstract

Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum based chemotherapeutics.

IPC Classes  ?

  • A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
  • A61K 33/243 - PlatinumCompounds thereof
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/08 - Solutions
  • A61K 33/04 - Sulfur, selenium or telluriumCompounds thereof
  • A61K 47/02 - Inorganic compounds
  • A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids

18.

PEDMARK

      
Serial Number 90071857
Status Registered
Filing Date 2020-07-24
Registration Date 2021-10-26
Owner Fennec Pharmaceuticals, Inc. ()
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations, namely, sodium thiosulfate used for the prevention of ototoxicity from cisplatin in pediatric patients

19.

ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF

      
Application Number US2019040051
Publication Number 2020/009953
Status In Force
Filing Date 2019-07-01
Publication Date 2020-01-09
Owner FENNEC PHARMACEUTICALS, INC. (USA)
Inventor
  • Lovelace, Thomas, Claiborne
  • Moore, Joseph, Alexander Iii
  • Lee, Christopher, Mckinnon
  • Kirschner, Daniel, Logan

Abstract

Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum based chemotherapeutics.

IPC Classes  ?

  • C01B 17/64 - ThiosulfatesDithionitesPolythionates
  • A61K 33/00 - Medicinal preparations containing inorganic active ingredients
  • A61K 33/04 - Sulfur, selenium or telluriumCompounds thereof
  • C01B 17/00 - SulfurCompounds thereof

20.

Anhydrous sodium thiosulfate and formulations thereof

      
Application Number 16458261
Grant Number 10792363
Status In Force
Filing Date 2019-07-01
First Publication Date 2020-01-09
Grant Date 2020-10-06
Owner
  • ADS PHARMA CONSULTING, LLC (USA)
  • FENNEC PHARMACEUTICALS, INC. (USA)
Inventor
  • Lovelace, Thomas Claiborne
  • Moore, Iii, Joseph Alexander
  • Lee, Christopher Mckinnon
  • Kirschner, Daniel Logan

Abstract

Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum based chemotherapeutics.

IPC Classes  ?

  • A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
  • A61K 33/243 - PlatinumCompounds thereof
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/08 - Solutions
  • A61K 33/04 - Sulfur, selenium or telluriumCompounds thereof
  • A61K 47/02 - Inorganic compounds
  • A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids

21.

FORMULATIONS OF ANHYDROUS SODIUM THIOSULFATE

      
Application Number US2019040052
Publication Number 2020/009954
Status In Force
Filing Date 2019-07-01
Publication Date 2020-01-09
Owner FENNEC PHARMACEUTICALS, INC. (USA)
Inventor
  • Lee, Christopher, Mckinnon
  • Lovelace, Thomas, Claiborne
  • Moore, Joseph, Alexander, Iii
  • Kirschner, Daniel, Logan

Abstract

Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum based chemotherapeutics.

IPC Classes  ?

22.

METHOD FOR REDUCING OTOTOXICITY IN PEDIATRIC PATIENTS RECEIVING PLATINUM-BASED CHEMOTHERAPY

      
Application Number US2018062750
Publication Number 2019/108592
Status In Force
Filing Date 2018-11-28
Publication Date 2019-06-06
Owner FENNEC PHARMACEUTICALS, INC. (USA)
Inventor
  • Neuwelt, Edward, A.
  • Knight, Kristin

Abstract

Described herein is a method for eliminating or reducing ototoxicity in patients receiving a platinum based chemotherapeutic. In particular, are methods of reducing ototoxicity in a pediatric patient. The methods described herein include administering an effective amount of sodium thiosulfate to a patient in need thereof to reduce ototoxicity.

23.

PEDMARK

      
Application Number 016992745
Status Registered
Filing Date 2017-07-17
Registration Date 2017-12-12
Owner Fennec Pharmaceuticals, Inc. (USA)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations, namely, sodium thiosulfate used for the prevention of ototoxicity from cisplatin in pediatric patients; pharmaceutical preparations, namely, sodium thiosulfate; pharmaceutical preparations for the prevention of ototoxicity.

24.

PEDMARK

      
Serial Number 87305680
Status Registered
Filing Date 2017-01-18
Registration Date 2020-09-29
Owner Fennec Pharmaceuticals, Inc. ()
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations, namely, sodium thiosulfate used for the prevention of ototoxicity from cisplatin in pediatric patients